Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 4/2001

01-04-2001 | Review Article

Oxidative Damage and Schizophrenia

An Overview of the Evidence and Its Therapeutic Implications

Authors: Dr Jeffrey K. Yao, Ravinder D. Reddy, Daniel P. van Kammen

Published in: CNS Drugs | Issue 4/2001

Login to get access

Abstract

Free radicals are highly reactive chemical species generated during normal metabolic processes, which in excess can lead to membrane damage. Elaborate anti-oxidant defence systems exist to protect against oxidative stress.
There is accumulating evidence of altered antioxidant capacity in schizophrenia. Membrane dysfunction can be secondary to free radical-mediated pathology, and may contribute to specific aspects of schizophrenic symptomatology and complications of its treatment. Specifically, free radical-mediated abnormalities may contribute to the development of a number of clinically significant consequences, including prominent negative symptoms, tardive dyskinesia, neurological ‘soft’ signs and parkinsonian symptoms. Our previous results showing altered membrane dynamics and antioxidant enzyme activities in schizophrenia, and findings from other investigators, are consistent with the notion of free radical-mediated neurotoxicity in schizophrenia. These findings provide a theoretical basis from which the development of novel therapeutic strategies such as fatty acid and antioxidant supplementation can occur in the future.
Footnotes
1
1In the studies referred to throughout the rest of this article, patients with chronic schizophrenia were being treated with antipsychotics, unless stated otherwise.
 
Literature
1.
Liebennan JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 1993; 19: 371–429CrossRef
2.
Horrobin DF, Glen AIM, Hudson CJ. Posssible relevance of phosplolipid abnormalities and genetic interactions in psychiatric disorders; the relationship between dyslexia and schizophrenia. Med Hypotheses 1995; 45: 605–13PubMedCrossRef
3.
Yao JK. Red blood cell and platelet fatty acid metabolism in schizophrenia. In: Peet M, Glen I, Horrobin DF, editors. Phospholipid spectrum disorder in psychiatry. Lancashire: Marius Press, 1999: 57–71
4.
Yao JK, Reddy RD. Fatty acids and psychiatric disorders. In: Chow CK, editor. Fatty acid in foods and their health implications. 2nd ed. New York (NY): Marcel Dekker, 2000: 995–1012
5.
Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 1994; 13(3): 217–6
6.
Yao JK, van Kammen DP, Welker JA, et al. Red blood cell membrane dynamics in schizophrenia. III Correlation of fatty acid abnormalities with clinical measures. Schizophr Res 1994; 13(3): 227–32
7.
Yao JK, Leonard S, Reddy R. Membrane phospholipid abnormalities in portmortem brains from schizophrenic patients. Schizophr Res 2000; 42(1): 7–17PubMedCrossRef
8.
Vaddadi KS, Courtney P, Gilleard CS, et al. A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 1989; 27: 313–23PubMedCrossRef
9.
Horrobin DF, Manku MS, Hillman H, et al. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 1991; 30: 795–805PubMedCrossRef
10.
Glen AIM, Glen EMT, Horrobin DF, et al. A red cell membrane abnormality in a sub-group of schizophrenic patients: Evidence for two diseases. Schizophr Res 1994; 12; 53–61PubMedCrossRef
11.
Peet M, Laugharne JDE, Rangarajan N, et al. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 1995; 29: 227–32PubMedCrossRef
12.
Reddy RD, Yao JK. Membrane protective strategies in schizophrenia: conceptual and treatment issues. In: Peet M, Glen I, Horrobin DF, editors. Phospholipid spectrum disorder in psychiatry. Lancashire UK: Marius Press, 1999: 75–88
13.
Cadet JL, Lohr JB. Free radicals and the developmental pathology of schizophrenic burnout. Integr Psychiatry 1987; 5: 40–8
14.
Lohr JB. Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiatry 1991; 48: 1097–6PubMedCrossRef
15.
Mahadik SP, Mukherjee S. Free radical pathology and anti-oxidant defense in schizophrenia: a review. Schizophr Res 1996; 19: 1–17PubMedCrossRef
16.
Smythies J. Oxidative reactions and schizophrenia: a review-discussion. Schizophr Res 1997; 24(3): 357–64PubMedCrossRef
17.
Halliwell B, Gutteridge JMC. Oxygen radicals and the central nervous system. Trends Neurosci 1984; 8: 22–66CrossRef
18.
Kalyanaraman B. Free radicals from catecholamine hormones, neuromelanins, and neurotoxins. In: Miquel J, Quintanilha AT, Weber H, editors. Handbook of free 107 radicals and antioxidants in biomedicine. Vol. I. Boca Raton: CRC Press, 1989: 147–59
19.
Rice-Evans CA. Formation of free radicals and mechanisms of action in normal biochemical processes and pathological states. In: Rice-Evans CA, Burdon RH, editors. Free radical damage and its control. Amsterdam: Elsevier, 1994: 131–53CrossRef
20.
Ernster L. Lipid peroxidation in biological membranes mechanisms and implications. In: Yagi K, editor. Active oxygens, lipid peroxides, and antioxidants. Tokyo: CRC Press 1993: 11–38
21.
Chan PH, Fishman RA. Transient formation of superoxide radicals in polyunsaturated fatty acid-induced brain swelling. J Neurochem 1980; 35: 1004–7PubMedCrossRef
22.
Chan PH, Fishman RA, Longar S, et al. Cellular and molecular effects of polyunsaturated fatty acids in brain ischemia and injury. Prog Brain Res 1985; 63: 227–35PubMedCrossRef
23.
Smith C. Free radical mechanisms of tissue injury. In: Moslen M, Smith C, editors. Free radical mechanisms of tissue injury. Boca Raton: CRC Press, 1992; 1: 1–22
24.
Kaiya H, Horrobin DF, Manku MS, et al. Essential and other fatty acids in plasma in schizophrenic and normal individual from Japan. Biol Psychiatry 1991; 30: 357–62PubMedCrossRef
25.
Deby C, Deby-Dupont G. Oxygen species in prostaglandin biosynthesis in vitro and in vivo. In: Bannister WH, Bannister JV, editors. Development in biochemistry. Vol. 11B: biological and clinical aspects of superoxide and superoxide dismutase. New York (NY): Elsevier, 1980: 84–97
26.
Rotrosen J, Wolkin A. Phospholipid and prostaglandin hypotheses of schizophrenia. In: Meltzer NY, editor. Psychopharmacology: the third generation on progress. New York (NY): Raven Press, 1987: 759–64
27.
van Kammen DP, Yao JK, Goetz K. Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann N Y Acad Sci 1989; 559: 411–23PubMedCrossRef
28.
Rafalowska U, Liu GJ, Floyd RA. Peroxidation induced changes in synaptosomal transport of dopamine and g-aminobutyric acid. Free Radic Biol Med 1989; 6: 485–92PubMedCrossRef
29.
Pellmar T. Electrophysiological correlates of peroxide damage in guinea pig hippocampus in vitro. Brain Res 1986; 364: 377–81PubMedCrossRef
30.
Levin EY, Kaufman S. Studies on the enzyme catalyzing the conversion of 3,4-dihydroxyphenylethylamine to norepinephrine. J Biol Chem 1961; 236: 2043–4PubMed
31.
Schwartz RD, Skolnick P, Paul SM. Regulation of gamma-aminobutyric acid/barbiturate receptor-gated chloride ion flux in brain vesicles by phospholipase A2: possible role of oxygen radicals. J Neurochem 1988; 50: 565–71PubMedCrossRef
32.
Bartosz G. Free radicals and the developmental pathology of schizophrenic burnout [commentary]. Integr Psychiatry 1987 5: 43–4
33.
Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59: 1609–23PubMedCrossRef
34.
Hoffer A, Osmond H, Smythies J. Schizophrenia: a new approach. J Ment Sci 1954; 100: 29–5PubMed
35.
Michelson AM, Puget K, Durosay P, et al. Clinical aspects of the dosage of erythrocuprein. In: Michelson AM, McCord JM, Fridovich I, editors. Superoxide and superoxide dismutase. London: Academic Press, 1977; 467–99
36.
Wayner DDM, Burton GW, Ingold KU, et al. The relative contribution of vitamine E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim Biophys Acta 1987; 924: 408–19PubMedCrossRef
37.
Miller NJ, Rice-Evans C, Davies MJ, et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407–12PubMed
38.
Yao JK, Reddy R, McElhinny LG, et al. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998; 32: 1–8PubMedCrossRef
39.
Yao JK, Reddy RD, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000; 97: 137–51PubMedCrossRef
40.
Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998; 80: 29–39PubMedCrossRef
41.
Oke AF, May L, Adams RN. Ascorbic acid distribution patterns in human brain. In: Burns JJ, Rivers JM, Machlin LJ, editors. Third Conference on Vitamin C. Ann N Y Acad Sci 1987; 498: 1–12
42.
Rebec GV. Ascorbate: an antioxidant neuroprotectant and extracellular neuromodulator. In: Connor JR, editor. Metals and oxidative damage in neurological disorders. New York (NY): Plenum Press, 1997: 149–73
43.
Suboticanec K, Folnegovic-Smalc V, Korbar M, et al. Vitamin C status in chronic schizophrenia. Biol Psychiatry 1990; 28: 959–66PubMedCrossRef
44.
McCreadie RG, MacDonald E, Wiles D, et al. The nithsdale schizophrenia surveys. XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and normal subjects. Br J Psychiatry 1995; 167: 610–17
45.
Brown K, Reid A, White T, et al. Vitamin E, lipids, lipid peroxidation products and tardive dyskinesia. Biol Psychiatry 1998; 43: 863–67PubMedCrossRef
46.
Abdalla DSP, Manteiro HP, Olivera JAC. et al. Activities of Superoxide dismutase and glutathione peroxidase in schizophrenic and manic depressive patients. Clin Chem 1986; 32: 805–7
47.
Golse B, Debray-Ritzen P, Puget K, et al. Dosages érythrocytaires et plaquettes des superoxyde dismutases (1 et 2) et de la glutathion peroxydase dans les pychoses infantiles de développement. Nouv Presse Med 1978; 7: 1952PubMed
48.
Golse B, Debray Q, Puget K, et al. Dosages érythrocytaires de la superoxyde dismutases 1 et de la glutathion peroxydase dans les schizophrénies de l’adulte. Nouv Presse Med 1978; 7: 2070–1PubMed
49.
Reddy R, Mahadik SP, Mukherjee M, et al. Enzymes of the antioxidant system in chronic schizophrenic patients. Biol Psychiatry 1991; 30: 409–12PubMedCrossRef
50.
Yao JK, Reddy R, McElhinny LG, et al. Effect of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998; 32: 385–91PubMedCrossRef
51.
Sinet PM, Debray Q, Carmagnol F, et al. Normal erythrocyte SOD values in two human diseases: schizophrenia and cystic fibrosis. In: Greenwald RA, Cohen G, editors. Oxy radicals and their scavenger systems. Vol. II. Cellular and medical aspects. New York (NY): Elsevier, 1983: 302–4
52.
Khan NS, Das I. Oxidative stress and superoxide dismutase in schizophrenia. Biochem Soc Trans 1997; 25(3): 418S
53.
Mukherjee S, Mahadik SP, Scheffer R, et al. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996; 19: 19–26CrossRef
54.
Stoklasova A, Zapletalek M, Kudrnova K, et al. Glutathione peroxidase activity of blood in chronic schizophrenics [in Czech]. Sb Ved Pr Lek Fak Karlovy University Hradci Kralove Suppl. 1986; 29(1–2): 103–8
55.
Golse B, Debray-Ritzen P, Puget K, et al. Dosages de la superoxyde dismutases 1 plaquettaire dans les pychoses infantiles de développement. Nouv Presse Med 1977; 6: 2449PubMed
56.
Zhang ZJ, Ramchand CN, Ramchand R, et al. Glutathione peroxidase (GSHPx) activity in plasma and fibroblasts from schizophrenics and control. Biol Psychiatry 1998; 29: 103–4
57.
Yao JK, Reddy R, van Kammen DP. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol Psychiatry 1999; 45: 1512–5PubMedCrossRef
58.
Buckman TD, Kling AS, Eiduson S, et al. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: Relation to psychosocial variables. Psychiatry Res 1990; 31: 1–14PubMedCrossRef
59.
Harman D. Aging prospects for future increases in the functional life span. Age 1994; 17: 119–46CrossRef
60.
Vanella A, Goremia E, D’Urso G, et al. Superoxide dismutase activity in aging rat brian. Gerontology 1982; 228: 108–3CrossRef
61.
Marvilli L, Mondov B, Federicop R, et al. Superoxide dismutase activity in developing rat brian. J Neurochem 1978; 31: 363–4CrossRef
62.
Hiramastsu M, Kohno M, Edamatsu R, et al. Increased superoxide dismutase activity in aged human cerebrospinal fluid and rat brain determined by electron spin resonance spectrometry using spin trap method. J Neurochem 1992; 58: 116–4CrossRef
63.
Mori A, Packer L. Disorders of the oxidative stress defense system in senescence-accelerated mice (SAM, and prolongation of life span by supplementation with antioxidants and free radical spin traps. In: Packer L, Ong A, editors. Biological oxidants and antioixidants: molecular mechanisms and health effects. Champaign (IL): AOCS Press, 1998: 327–4
64.
Sohal RS, Ku HH, Agarwal S, et al. Oxidative damage, mitochondrial oxidant generation and antioxidant defenses during aging and in response to food restriction in the mouse. Mech Ageing Dev 1994; 74: 121–33PubMedCrossRef
65.
Shigenaga MK, Hagen T, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A 1994; 91: 10771–8PubMedCrossRef
66.
67.
Miquel J, Economos AC, Fleming J, et al. Mitochondrial role in cell aging. Exp Gerontol 1998; 15: 575–91CrossRef
68.
Clapp NK, Satterfield LC, Bowler ND. Effects of the antioxidant butyrated hydroxyltoluence(BHT) on mortality in BALB/C mice. J Gerontol 1979; 34: 497–50PubMedCrossRef
69.
Comfort A. Effect of ethoxyquin on longevity of c3h mice. Nature 1991; 229: 254–5CrossRef
70.
Heidrick ML, Heidrick LC, Cook DE. Effect of dietary 2-mercaptoethanol on the life span, immune system, tumor incidence and lipid peroxidation damage in spleen lymphocytes of aging bc3f mice. Mech Aging 1984; 27: 341–58CrossRef
71.
Harman D. The aging process. Proc Natl Acad Science U S A 1981; 78: 7124–8CrossRef
72.
Mukherjee S, Mahadik SP, Correnti EE. The antioxidant defense system at the onset of psychosis. Biol Psychiatry 1994; 35: 701
73.
Szabo L, Lajko K, Barabas K, et al. Effects of neuroleptics on lipid peroxidation and peroxide metabolism enzyme activities in various discrete areas of the rat brain. Gen Pharmacol 1983; 14: 537–39PubMedCrossRef
74.
Ohtsuka Y, Yabunaka N, Fujisawa H, et al. Effect of thermal stress on glutathione metabolism in human erythrocytes. Euro J Appl Physiol Occup Physiol 1994; 68: 87–91CrossRef
75.
Scarpellini F, Sbracia M, Scarpellini L. Psychological stress and lipoperoxidation in miscarriage. Ann N Y Acad Sci 1994; 709: 210–3PubMedCrossRef
76.
Hughes R, Hatsukami K, Mitchell E, et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143: 993–7PubMed
77.
78.
Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite continine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997; 42: 1–5PubMedCrossRef
79.
Church DF, Pryor WA. Free radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perpect 1985; 64: 111–26CrossRef
80.
Chow KC.Vitamin E and cigarette smoking-induced oxidative damage. In: Packer L, Fuchs J, editors. Vitamin E in health and disease. New York: Marcel Decker, 1992: 683–97
81.
Pryor WA, Stone K. Oxidants in cigarette smoke. Ann N Y Acad Sci 1992; 686: 29
82.
Stegmayr B, Johansson I, Huhtasaari F, et al. Use of smokeless tobacco and cigarettes: effects on plasma levels of antioxidant vitamins. Int J Vitam Nutr Res 1993; 63: 195–200PubMed
83.
84.
Papas AM. Determinants of antioxidant status in humans. Lipids 1996; 31 Suppl.: 77S–82SCrossRef
85.
Becker K, Boetticher D, Leichsenring M. Antioxidant vitamins in malnourished Nigerian children. Int J Vitam Nutr Res 1994; 64: 306–10PubMed
86.
Parfitt VJ, Rubba P, Bolton C, et al. A comparison of antioxidant status and free radical peroxidation on plasma lipoproteins in healthy young persons from Naples and Bristol. Eur Heart J 1994; 15: 871–6PubMed
87.
Lecomte E, Herbeth B, Pirollet P et al. Effect of alcohol consumption on blood antioxidant nutrients and oxidative stress indicators. Am J Clin Nutr 1994; 60: 255–61PubMed
88.
Evans DR, Puczkovski PY, Brandsma MJ, et al. Elevated plasma lipid peroxides in schizophrenic patients without dementia. Biol Psychiatry 1996; 39: 588CrossRef
89.
Guliaeva NV, Levshina IP, Obidin AM. Indices of lipid free radical oxidation and the antiradical protection of the brain: the neurochemical correlates of the development of the general adaptation syndrome. Zh Vyssh Nerv Deiat Im I P Paviova 1988; 38: 731–37
90.
Peet M, Laugharne J, Rangarajan N et al. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993; 8: 151–53PubMedCrossRef
91.
Prilipko LL. The possible role of lipid peroxidation in the pathophysiology of mental disorders. In: Packer L, Prilipko L, Christen Y, editors. Free radicals in the brain. Berlin: Spinger-Verlag, 1992: 146–52CrossRef
92.
Pall HS, Williams AC, Blake DR, et al. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 1987; II: 596–7CrossRef
93.
Lohr JB, Kuczenski R, Bracha HS, et al. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990; 28: 535–9PubMedCrossRef
94.
Mahadik SP, Mukherjee S, Scheffer R, et al. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998; 43: 674–79PubMedCrossRef
95.
Kovaleva ES, Orlov ON, Tsutsul’kovskia MIA, et al. Lipid peroxidation processes in patients with schizophrenia. Zh Nevropatol Psikiatr 1989; 89: 108–10
96.
Phillips M, Sabas M, Greenberg J. Increased pentane and carbon disulfide in the breath of patients with schizophrenia. J Clin Pathol 1993; 46: 861–4PubMedCrossRef
97.
Floyd RA. Mitochondrial damage in neurodegenerative disease. In: Packer L, Hiramatsu M, Yoshikawa T, editors. Free radicals in brain physiology and disorders. San Diego (CA): Academic Press, 1996: 313–29
98.
Cavelier L, Jazin EE, Eriksson I, et al. Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics 1995; 29: 217–24PubMedCrossRef
99.
Radi R, Castro L, Rodriguez M, et al. Free radical damage to mitochondria. In: Beal MF, Howell N, Bodis-Wellner I, editors. Mitochondria and free radicals in neurodegenerative diseases. New York (NY): Wiley-Liss, 1997: 57–89
100.
Buchsbaum MS, Neuchterlein KH, Haier RJ, et al. Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by Positron Emission Tomography. Br J Psychiatry 1990; 156: 217–7CrossRef
101.
Wise CD, Baden MM, Stein L. Post-mortem measurement of enzymes in human brain: evidence of a central noradrenergic deficit in schizophrenia. J Psychiatr Res 1974; 11: 185–98PubMedCrossRef
102.
Loven DP, James JF, Biggs L, et al. Increased manganese-superoxide dismutase activity in postmortem brain from neuroleptic-treated psychotic patients. Biol Psychiatry 1996; 40: 230–32PubMedCrossRef
103.
Miyakawa T, Sumiyoshi Deshimaru M. Electron microscopic study on schizophrenia: mechanism of pathological changes. Acta Neuropathol (Berlin) 1972; 20: 67–77CrossRef
104.
Averback P. Structural lesions of the brain of young schizophrenics. Can J Neurol Sci 1981; 8: 73–6PubMed
105.
Senitz D, Winkelmann E. Über morphologische befunde in der orbitofrontalen rinde bei menschen mit schizophrenen psychosen. Eine golgi-und eine elektonenoptische Studie. Psychiatr Neurol Med Psychol Beih 1981; 33: 1–9
106.
107.
Kane J, Lieberman J, Woerner M, et al. Tardive dyskinesia: New Research. In: Schulz SC, Tamminga CA, editors. Schizophrenia. New York (NY): Scientific Progress Oxford University Press 1989: 381–86
108.
Crow TJ, Cross AJ, Johnstone EC, et al. Abnormal involuntary movements in schizophrenia: Are they related to the disease process or its treatment? Are they associated with changes in the dopamine receptors? J Clin Psychopharmacol 1982; 2: 336–40PubMedCrossRef
109.
Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosci 1986; 9: 107–8CrossRef
110.
Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci 1989; 570: 176–85
111.
Zubenko GS, Cohen BM. A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines. Psychopharmacology 1986; 88: 230–36PubMedCrossRef
112.
Lohr JB, Cadet JL, Lohr MA, et al. Alpha-tocopherol in tardive dyskinesia. Lancet 1987; I: 913–4CrossRef
113.
Elkashef AM, Ruskin PE, Bacher N, et al. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry 1990; 147: 505–6PubMed
114.
Keshaven MS, Mallinger AG, Pettegrew JW, et al. Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res 1993; 49: 89–95CrossRef
115.
Mahadik SP, Mukherjee S, Correnti E, et al. Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res 1994; 13: 239–47PubMedCrossRef
116.
Horrobin DF, Manku MS, Morse-Fisher N, et al. Essential fatty acids in plasma phospholipids in schizophrenics. Biol Psychiatry 1989; 25: 562–8PubMedCrossRef
117.
Peet M, Laugharne JDE, Mellor J, et al. Essential fatty acid deficiency in eyrthrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 71–5PubMedCrossRef
118.
Mahadik SP, Mukherjee S, Correnti EE, et al. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar and normal controls. Psychiatry Res 1996; 63: 133–42PubMedCrossRef
119.
Reddy RD, Yao JK, Zeigler M, et al. Essential fatty acids and outcome in first-episode schizophrenia. Schizophr Res 1999; 36: 108
120.
Yao JK, Stanley JA, Reddy RD, et al. Correlations between RBC fatty acids and 31P MRS brain measures in schizophrenia. Biol Psychiatry 2000; 47: 41SCrossRef
121.
Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukotr Essent Fatty Acids 1996; 55: 3–7CrossRef
122.
Pettegrew JW, Keshavan MS, Panchalingam K, et al. Alterations in brain high energy phosphate and membrane phospholipid metabolism in first episode drug naive schizophrenics. Arch Gen Psychiatry 1991; 48: 563–8PubMedCrossRef
123.
Pettegrew JW, Keshaven MS, Minshew NJ. 31P nuclear magnetic resonance spectroscopy: Neuro-development and schizophrenia. Schizophr Bull 1993; 19: 335–53CrossRef
124.
Deicken RF, Merrin E, Calabrese G, et al. 31Phosphorus MRSI in the frontal and parietal lobes in schizophrenia. Biol Psychiatry 1993; 33: 46A
125.
Fukazako H, Takeuchi K, Fujimoto T, et al. 31P magnetic resonance spectroscopy of schizophrenic patients with neuroleptic resistant positive and negative symptoms. Biol Psychiatry 1992;31: 204A-5A
126.
Fukuzako H, Fukuzako T, Takeuchi K, et al. Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in temporal lobe and positive symptoms. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 629–40PubMedCrossRef
127.
Stanley JA, Williamson PC, Drost DJ, et al. The study of schizophrenia via in vivo 31P and 1H MRS. Schizophr Res 1993; 9: 210CrossRef
128.
Williamson P, Drost D, Stanley J, et al. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls [letter]. Arch Gen Psychiatry 1991; 48: 578PubMedCrossRef
129.
Keshaven MS, Pettegrew JW, Ward R. Are membrane phospholipid changes in schizophrenia familial? Biol Psychiatry 1993; 33: 37A-162A
130.
Cohen G. Enzymatic/nonenzymatic sources of oxyradicals and regulation of antiodant defences. Ann N Y Acad Sci 1994; 738: 8–14PubMedCrossRef
131.
Zhang F, Dryhurst G. Effects of 1-cysteine on the oxidative chemistry of dopamine: new reaction pathways of potential relevance to ideopathic Parkinson’s disease. J Med Chem 1994; 37: 1084–98PubMedCrossRef
132.
Ben-Shacher D, Zuk B, Glinka Y. Dopamine neurotoxicity: Inhibition of mitochondrial respiration. J Neurochem 1995; 64: 718–23CrossRef
133.
Cadet JL, Kahler LA. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 1994; 18:457–67PubMedCrossRef
134.
Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990; 76: 428–35CrossRef
135.
Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neuro-degenerative disorders. Science 1993; 262: 689–95PubMedCrossRef
136.
Patel M, Day BJ, Crapo JD, et al. Requirement for superoxide in excitotoxic cell death. Neuron 1996; 16: 345PubMedCrossRef
137.
Ciani E, Groneng L, Voltattorni M, et al. Inhibition of free radical production or free radical scavenging protects from excitatoxic cell death mediated by glutamate in cultures of cerebellar granule cells. Brain Res 1996; 728: 1–6PubMedCrossRef
138.
MacGregor DG, Higgins MJ, Jones PA, et al. Ascorbate attenuates the systemic kainate-induced neurotoxicity in the rat hippocampus. Brain Res 1996; 727: 133–44PubMedCrossRef
139.
Iuliano L, Pedersen JZ, Pratico D, et al. Role of hydroxyl radicals in the activation of human platelets. Eur J Biochem 1994; 221: 695–704PubMedCrossRef
140.
Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998–1007PubMedCrossRef
141.
Carlsson M, Carlsson A. Schizophrenia: a subcortical neuro-transmitter imbalance syndrome? Schizophr Bull 1990; 16: 425–32PubMedCrossRef
142.
Hitri A, Hurd YL, Wyatt RJ, et al. Molecular, functional and biochemical characteristics of the dopamine transporter: Regional differences and clinical relevance. Clin Neuropharm 1994; 17: 1–22CrossRef
143.
Maguire PA, Druse MJ. The influence of cholesterol on synap-tic fluidity and dopamine uptake. Brain Res Bull 1989; 22: 431–37PubMedCrossRef
144.
Hitri A, Casanova MF, Kleinman JE, et al. Age-related changes in [3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizphrenics. Biol Psychiatry 1995; 37: 175–82PubMedCrossRef
145.
Davidson B, Kurstjens NP, Patton J, et al. Essential fatty acids modulate apomorphine activity at receptors in cat caudate slices. Eur J Pharmacol 1988; 149: 317–22PubMedCrossRef
146.
147.
Felder CC, Kanterman RY, Ma AL, et al. Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. Proc Nat Acad Sci U S A 1990; 87: 2187–91CrossRef
148.
Yao JK, van Kammen DP, Moss HB, et al. A decreased serotonergic responsivity in platelets of unmedicated patients with Schizophrenia. Psychiatry Res 1996; 63: 123–32PubMedCrossRef
149.
Ohmori T, Abekawa T, Koyama T. The role of glutamate in the behavioral and neurotoxic effects of methamphetamine. Neurochem Int 1996; 29: 301–7PubMedCrossRef
150.
Yamada K, Kanba S, Anamizu S, et al. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. Psychol Med 1997; 27: 1223–5PubMedCrossRef
151.
Yao JK, van Kammen DP, Reddy RD, et al. Superoxide dismutase and negative symptoms in schizophrenia. Biol Psychiatry 1998; 43: 123S-4S
152.
Mahadik SP, Evans DR. Essential fatty acids in the treatment of schizophrenia. Drugs of Today 1997; 33: 5–17
153.
Reddy R, Yao JK. Schizophrenia: role of oxidative stress and essential fatty acids. In: Basu, Tk, Temple NJ, Garg ML, editors. Antioxidants in human health. Wallingford, Oxon: Cab International 1999; 27: 351–66
154.
Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukotr Essent Fatty Acids 1996; 55: 45–54CrossRef
155.
Mahadik SP, Gowda S. Antioxidants in the treatment of schizophrenia. Drugs of Today 1996; 32: 553–65
156.
Vatassery GT. Vitamin E: Neurochemical aspects and relevance to nervous system disorders. In: Connor JR. editor. Metals and oxidative damage in neurological disorders. New York (NY): Plenum Press, 1997: 175–88
157.
Duffy PH, Leakey JE, Pipkin JL, et al. The physiologic, neurologic and behavioral effects of caloric restriction related to aging, disease, and environmental factors. Environ Res 1997; 73: 242–8PubMedCrossRef
158.
Ryder MI, Fujitaki R, Johnson G, et al. Alterations of neutrophil oxidative burst by in vitro smoke exposure: implications for oral and systemic diseases. Ann Peridont 1998; 3: 76–87CrossRef
159.
DiLuzio NR, Hartman AD. Role of lipid peroxidation on the pathogenesis of the ethanol-induced fatty liver. Fed Proc 1967; 26: 1436
160.
Shaw S, Javatilleke E, Ross WA, et al. Ethanol-induced lipid peroxidation: Potentiation by long-term alcohol feeding and attenuation by methionine. J Lab Clin Med 1981; 98: 417PubMed
161.
Vatassery GT, Smith WE, Quach HT. A liquid chromatographic method for the simultaneous determination of α-tocopherol and tocopherolquinone in human red blood cells aqnd other biological samples where tocopherol is easily oxidized during sample treatment. Anal Biochem 1993; 214: 426–30PubMedCrossRef
162.
Sokol RJ. Vitamin E and neurologic function in man. Free Radie Biol Med 1989 6: 189–207CrossRef
163.
Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993; 50: 1405–7
164.
Egan MF, Hyde TM, Albers GW, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992; 149: 773–7PubMed
165.
Corrigan FM, Van Rhijn AG, Mackay AV, et al. Vitamin E treatment of tardive dyskinesia [letter]. Am J Psychiatry 1993; 150: 991–2PubMed
166.
Shriqui CL, Bradwejn J, Annable L, et al. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 1992; 149: 391–93PubMed
167.
Adler LA, Edson R, Lavori P, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998; 43: 868–72PubMedCrossRef
168.
169.
Sram RJ, Binkova B. Side effects of psychotropic therapy. In: Packer L, Prilipko L, Christen Y, editors. Free radicals in the brain. Berlin: Spinger-Verlag, 1992: 153–66CrossRef
170.
World Health Organization. Schizophrenia: an international follow-up study. New York: Wiley 1979
171.
Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiat Scand 1988; 78: 587–91PubMedCrossRef
172.
Horrobin DF. The relationship between schizophrenia and essential fatty acids and eicosanoid production. Prostaglandins Leukotr Essent Fatty Acids 1992; 46: 71–7CrossRef
173.
Nohria V, Vaddadi KS. Tardive dyskinesia and essential fatty acids: an animal model study. In: Horrobin DF, editor. Clinical Uses of Essential Fatty Acids. Montreal: Eden Press 1982: 199–204
174.
Costall B, Kelly M, Naylor RJ. The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent. Br J Pharmacol 1984; 83: 733–40PubMedCrossRef
175.
Bourguignon A. Trial of evening primrose oil in the treatment of schizophrenia. L’Encephale 1984; 10: 241–50PubMed
176.
Soulairac A, Lambinet H, Neuman JC. Schizophrenia and PGs: Therapeutic effects of PG precursors in the form of evening primrose oil. Ann Med Psychol (Paris) 1983; 8: 883–90
177.
Wolkin A, Jordan B, Peselow E, et al. Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry 1986; 143: 912–14PubMed
178.
Vaddadi KS. Dyskinesias and their treatment with essential fatty acids: A review. Prostaglandins, Leukotr Essent Fatty Acids 1996; 55: 89–94CrossRef
179.
Mellor JE, Laugharne JDE, Peet M. Omega-3 fatty acid supplementation in schizophrenia patients. Hum Psychopharmacol 1996; 11: 39–46CrossRef
180.
Shah S, Vankar GK, Telang SD, et al. Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia. Schizophr Res 1998; 20: 158CrossRef
181.
Peet M. New Strategies for the treatment of schizophrenia: ω-3 polyunsaturated fatty acids. In: Peet M, Glen I, Horrobin D, editors. Phospholipid spectrum disorder in psychiatry. Lancashire: Marius Press 1999: 18: 189–92
182.
Puri BK, Richardson AJ, Horrobin DF, et al. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int J Clin Pract 2000; 54: 57–63PubMed
183.
184.
Jesberger JA, Richardson JS. Oxygen free radicals and brain dysfunction. Int J Neurosci 1991; 57: 1–17PubMedCrossRef
185.
Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull 1999; 25: 731–40PubMedCrossRef
186.
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330: 1029–35CrossRef
187.
188.
Richardson A, Easton T, McDaid AM, et al. Essential fatty acids in dyslexia: theory, evidence and clinical trials. In: Peet M, Glen I, Horrobin DF, editors. Phospholipid spectrum disorder in psychiatry. Lancashire: Marius Press. 1999: 21: 225–41
189.
Stordy B. Long-chain fatty acids in the management of dyslexia and dyspraxia. In: Peet M, Glen I, Horrobin DF, editors. Phospholipid Spectrum disorder in psychiatry. Lancashire: Marius Press 1999; 23: 251–60
190.
Fenton W, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000; 47: 8–21PubMedCrossRef
Metadata
Title
Oxidative Damage and Schizophrenia
An Overview of the Evidence and Its Therapeutic Implications
Authors
Dr Jeffrey K. Yao
Ravinder D. Reddy
Daniel P. van Kammen
Publication date
01-04-2001
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 4/2001
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200115040-00004

Other articles of this Issue 4/2001

CNS Drugs 4/2001 Go to the issue

Therapy in Practice

Sleep Disorders in Patients with Parkinson’s Disease

Guest Commentaries

Perospirone

Current Opinion

Glucose for Smoking Cessation

Adis New Drug Profile

Perospirone

Review Article

The Role of Central Serotonergic Dysfunction in the Aetiology of Premenstrual Dysphoric Disorder

Guest Commentaries

Perospirone